AnaptysBio, Inc.
http://www.anaptysbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AnaptysBio, Inc.
BI Prepares For Regulatory Filings After Spevigo Successfully Prevents GPP Flares
The German firm’s Spevigo seems set to dominate the generalized pustular psoriasis market after it reduced the risk of flares in the pivotal EFFISAYIL 2 trial, triggering label expansion plans less than a year after it was approved for flare treatment.
UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success
Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.
Novartis’s Cosentyx Secures Qualified Win In Hidradenitis Suppurativa
The Swiss major’s Cosentyx has succeeded in two trials for the debilitating skin condition but there are concerns that the data may not be sufficient to shift AbbVie’s Humira off the top spot for treatment.
Boehringer’s Spesolimab Wins First Approval In Rare Skin Condition
The German firm’s monoclonal antibody has received a US thumbs-up for a severe skin disease with high unmet need but it must address diagnostic and educational hurdles.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice